Sarcoma, Soft Tissue Clinical Trial
Official title:
Phase II Study Evaluating Adaptive Radiation Therapy in Pre-operative or Exclusive Radiation Therapy for Limb Soft Tissues Sarcomas
Soft tissue sarcomas (STS) is generally treated by surgery, followed or preceded by
radiotherapy and chemotherapy. Preoperative irradiation has been shown to be effective in a
randomized trial, and is often indicated in locally advanced Soft tissue sarcomas of the
limbs, in order to reach R0 resection, or in case of rapid tumor growth despite first
chemotherapy. For inoperable sarcomas, radiotherapy is an efficient palliative treatment,
increasing local control.
Adaptive radiotherapy is defined as the set of procedures leading to the modification of a
treatment plan based on the individual variations observed during irradiation. The place of
this technique is increasing since the development of image-guided-radiotherapy allowing the
visualization of daily variations in position, shape or volume of the tumor and organs at
risk. Its implementation in current practice however remains limited because of the
cumbersome processes involved (new delineation, new dose calculation, or even
re-optimization) and resources to commit, especially in human time.
Irradiation of soft tissue sarcomas always begins with a planning CT scan, where the
target-volumes and organ at risk are delineated, and dosimetric calculations are performed
prior to radiotherapy initiation. During the radiotherapy, the variations leading to a
mismatch between the planned dose and the dose delivered are multiple. These may be due to
positioning errors or morphological changes in the patient (weight loss), or in the tumor or
organs at risk (modifications in shape, size or position). The volume of soft tissue sarcomas
changes also during radiotherapy (response, progression or pseudo- progression of the tumor).
However, to date, few data are available in the literature both on the volume variation of
soft tissue sarcomas during preoperative radiotherapy, and on the interest of adaptive
radiotherapy in the management of these tumors. It is therefore necessary to evaluate whether
modifications of growth or macroscopic tumor volume are observed during the treatment, and to
evaluate dosimetric impact on the target volume coverage that could impact the results of the
treatment.
This a prospective multicentric phase II trial conducted to evaluate the interest of adaptive
radiotherapy in the preoperative or exclusive management of limb sarcomas Patients will be
treated by preoperative or definitive radiotherapy for a limb soft tissue sarcomas, using an
intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7
consecutive weeks. The total dose delivered will be of 50 Gray (preoperative radiation
therapy), or 60 to 70 Gray (exclusive radiation therapy). The delineation of growth or
macroscopic tumor volume,clinical target volume, and planning target volume, as well as
healthy surrounding tissues will be carried out in each of the centers, and under the
responsibility of the radiotherapist, on The simulation CT-scan, used for dosimetry, and 3 CT
scan performed on day 1 of radiotherapy (d1), at a dose of 30Gy (d30Gy) and 50Gy (d50GY). The
dosimetric re-planning according to the variations of the volume of the planning target
volume will be done in case of significant variation of the target volume according to de
definition mentionned in the main and secondary objectives.
Main objective: The aim of this study is to evaluate the interest of adaptive radiotherapy in
the preoperative or exclusive management of limb sarcomas.
This is the first prospective trial focused on the evaluation of the volume variation of soft
tissue sarcomas during preoperative radiotherapy, and also on the interest of adaptive
radiotherapy in the management of these tumors, whereas indications of preoperative and/or
exclusive radiation therapy are very frequent.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03985722 -
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
|
Phase 1 | |
Withdrawn |
NCT02464332 -
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
|
Phase 1 | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Completed |
NCT00289809 -
TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01185964 -
A Study of IMC-3G3 in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00753688 -
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
|
Phase 3 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
Completed |
NCT03798795 -
Radiomics for Tumor Grading of Soft Tissue Sarcomas.
|
||
Terminated |
NCT02929394 -
Trabectedin Maintenance Post 1st-line in STS
|
Phase 3 | |
Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00406601 -
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT00297258 -
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT06114173 -
Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
|
Early Phase 1 | |
Completed |
NCT00061659 -
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT03815474 -
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
|
Phase 2 | |
Recruiting |
NCT02812654 -
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
|
Phase 2 | |
Completed |
NCT00204620 -
Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
|
Phase 2 | |
Completed |
NCT03058406 -
A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
|
||
Active, not recruiting |
NCT02415816 -
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
|
N/A |